MyRisk is the first hereditary cancer ... President and Chief Clinical Officer of Oncology, Myriad Genetics. “By making germline testing interoperable with OncoEMR, we aim to simplify the ...

Myriad’s MyRisk ® test is the first hereditary cancer test integrated into Flatiron’s OncoEMR ® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a ...

Myriad Genetics and agency partner S50 Health educated OBGYNs and their patients in a campaign called “Getting Ahead of ...

SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN) announced today a collaboration with Flatiron Health to integrate its MyRisk Hereditary Cancer Test into Flatiron's OncoEMR platform. This ...

SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN) announced today a collaboration with Flatiron Health to integrate its MyRisk Hereditary Cancer Test into Flatiron's OncoEMR platform.

(NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Flatiron Health, a leading health tech company dedicated to expanding the possibilities of ...

As part of the deal, providers will have access to Tempus' tests such as the xT solid tumor and normal match DNA sequencing test, xR whole-transcriptome sequencing RNA test, liquid biopsy-based xF/xF+ ...